scholarly journals Tbx1 regulates oral epithelial adhesion and palatal development

2012 ◽  
Vol 21 (11) ◽  
pp. 2524-2537 ◽  
Author(s):  
Noriko Funato ◽  
Masataka Nakamura ◽  
James A. Richardson ◽  
Deepak Srivastava ◽  
Hiromi Yanagisawa
Keyword(s):  
Palatal Development ◽  
Oral Epithelial

scholarly journals Novel Aggregation Properties of Candida albicans Secreted Aspartyl Proteinase Sap6 Mediate Virulence in Oral Candidiasis

2015 ◽  
Vol 83 (7) ◽  
pp. 2614-2626 ◽  
Author(s):  
Rohitashw Kumar ◽  
Darpan Saraswat ◽  
Swetha Tati ◽  
Mira Edgerton
Keyword(s):  
Candida Albicans ◽  
Epithelial Cells ◽  
Oral Candidiasis ◽  
Oral Microbiome ◽  
Proteinase Activity ◽  
Adhesion Properties ◽  
Content Type ◽  
Oral Epithelial Cells ◽  
Oral Epithelial ◽  
Cell Cell

Candida albicans, a commensal fungus of the oral microbiome, causes oral candidiasis in humans with localized or systemic immune deficiencies. Secreted aspartic proteinases (Saps) are a family of 10 related proteases and are virulence factors due to their proteolytic activity, as well as their roles in adherence and colonization of host tissues. We found that mice infected sublingually withC. albicanscells overexpressing Sap6 (SAP6OE and a Δsap8strain) had thicker fungal plaques and more severe oral infection, while infection with the Δsap6strain was attenuated. These hypervirulent strains had highly aggregative colony structurein vitroand higher secreted proteinase activity; however, the levels of proteinase activity ofC. albicansSaps did not uniformly match their abilities to damage cultured oral epithelial cells (SCC-15 cells). Hyphal induction in cells overexpressing Sap6 (SAP6OE and Δsap8cells) resulted in formation of large cell-cell aggregates. These aggregates could be produced in germinated wild-type cells by addition of native or heat-inactivated Sap6. Sap6 bound only to germinated cells and increasedC. albicansadhesion to oral epithelial cells. The adhesion properties of Sap6 were lost upon deletion of its integrin-binding motif (RGD) and could be inhibited by addition of RGD peptide or anti-integrin antibodies. Thus, Sap6 (but not Sap5) has an alternative novel function in cell-cell aggregation, independent of its proteinase activity, to promote infection and virulence in oral candidiasis.

scholarly journals The expression of the GATA6 gene in oral carcinoma cell lines

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Cheng-Lin Xu ◽  
Wei-Qun Guan ◽  
Xue-Ying Wang
Keyword(s):  
Cell Lines ◽  
Carcinoma Cell ◽  
Carcinoma Cells ◽  
Expression Levels ◽  
Carcinoma Cell Lines ◽  
Human Tongue ◽  
Adenoid Cystic ◽  
Significant Difference ◽  
Oral Epithelial ◽  
Gata6 Gene

Abstract Background This study aimed to investigate the expression level of the GATA6 gene in different oral cancer cells. Methods In this study, we sub-cultured normal oral epithelial cell lines HOK, human tongue squamous cell carcinoma cell lines CAL-27 and SCC-4, and human salivary gland adenoid cystic carcinoma cell lines SACC-LM and SACC-83. Subsequently, we used reverse transcription-polymerase chain reaction RT-PCR and Western blot methods to detect the mRNA and the protein expressions of GATA6 in normal oral epithelial cells, human tongue squamous cell carcinoma cells, and human salivary gland adenoid cystic carcinoma cells. Results The results of this study showed that the mRNA expression levels of GATA6 in CAL-27, SCC-4, and SACC-LM cells were significantly increased when compared with the HOK cells. However, the mRNA expression level of GATA6 in the SACC-83 cells had no significant difference compared with the HOK cells. The protein expression levels of GATA6 in the SCC-4 and SACC-LM cells were, however, significantly increased whereas the protein expression levels of GATA6 in the CAL-27 and SACC-83 cells had no significant difference when compared with the HOK cells. Conclusion The GATA6 gene may be related to the occurrence and progression of certain oral cancers.

scholarly journals SAVER: sodium valproate for the epigenetic reprogramming of high-risk oral epithelial dysplasia—a phase II randomised control trial study protocol

Trials ◽  
2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Caroline McCarthy ◽  
Joseph Sacco ◽  
Stefano Fedele ◽  
Michael Ho ◽  
Stephen Porter ◽  
...  
Keyword(s):  
High Risk ◽  
Sodium Valproate ◽  
Study Protocol ◽  
Epigenetic Reprogramming ◽  
Epithelial Dysplasia ◽  
Phase Iii ◽  
Cancer Development ◽  
Randomised Control Trial ◽  
Oral Epithelial Dysplasia ◽  
Oral Epithelial

Abstract Background Sodium valproate (VPA) has been associated with a reduced risk of head and neck cancer development. The potential protective mechanism of action is believed to be via inhibition of histone deacetylase and subsequent epigenetic reprogramming. SAVER is a phase IIb open-label, randomised control trial of VPA as a chemopreventive agent in patients with high-risk oral epithelial dysplasia (OED). The aim of the trial is to gather preliminary evidence of the clinical and biological effects of VPA upon OED and assess the feasibility and acceptability of such a trial, with a view to inform a future definitive phase III study. Methods One hundred and ten patients with high-risk OED will be recruited from up to 10 secondary care sites in the UK and randomised into either VPA or observation only for 4 months. Women of childbearing potential will be excluded due to the teratogenic properties of VPA. Tissue and blood samples will be collected prior to randomisation and on the last day of the intervention/observation-only period (end of 4 months). Clinical measurement and additional safety bloods will be taken at multiple time points during the trial. The primary outcome will be a composite, surrogate endpoint of change in lesion size, change in grade of dysplasia and change in LOH profile at 8 key microsatellite regions. Feasibility outcomes will include recruitment targets, compliance with the study protocol and adverse effects. A qualitative sub-study will explore patient experience and perception of the trial. Discussion The current management options for patients with high-risk OED are limited and mostly include surgical resection and clinical surveillance. However, there remains little evidence whether surgery can effectively lead to a notable reduction in the risk of oral cancer development. Similarly, surveillance is associated with concerns regarding delayed diagnosis of OED progressing to malignancy. The SAVER trial provides an opportunity to investigate the effects of a repurposed, inexpensive and well-tolerated medication as a potential chemopreventive strategy for patients with high-risk OED. The clinical and biological findings of SAVER will inform the appropriateness, design and feasibility of a definitive phase III trial. Trial registration The trial is registered with the European Clinical Trials Database (Eudra-CT 2018-000197-30). (http://www.isrctn.com/ISRCTN12448611). The trial was prospectively registered on 24/04/2018.

Observer agreement in the grading of oral epithelial dysplasia

2003 ◽  
Vol 31 (4) ◽  
pp. 300-305 ◽  
Author(s):  
Brothwell D. J ◽  
Lewis D. W ◽  
Bradley G ◽  
Leong I ◽  
Jordan R. C. K ◽  
...  
Keyword(s):  
Observer Agreement ◽  
Epithelial Dysplasia ◽  
Oral Epithelial Dysplasia ◽  
Oral Epithelial

Cytoprotective effects of opioids on irradiated oral epithelial cells

2013 ◽  
Vol 21 (6) ◽  
pp. 883-889 ◽  
Author(s):  
Nada Charbaji ◽  
Peter Rosenthal ◽  
Monika Schäfer-Korting ◽  
Sarah Küchler
Keyword(s):  
Epithelial Cells ◽  
Oral Epithelial Cells ◽  
Oral Epithelial
Sign in / Sign up

Export Citation Format

Share Document